Organogenesis Holdings Inc. - Class A (ORGO)
ORGO moved a median of -0.25% 30 minutes after news, and -0.47% by the close. How ORGO actually reacts to news — the realized, point-in-time move the market made, measured across 310 labeled events over the last three years with zero look-ahead.
ORGO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 309 |
| 30-min | -0.25% | 44% | 309 |
| 60-min | -0.48% | 44% | 309 |
| to close | -0.47% | 43% | 309 |
| Middle 50% of ORGO reactions | -1.23% to +0.88% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 310 |
Half of all Organogenesis Holdings Inc. - Class A news events land between -1.23% and +0.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ORGO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ORGO's baseline. Nothing else.
Recent ORGO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers | Press release | GlobeNewswire | -2.02% | -2.42% | |
| Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 | Press release | GlobeNewswire | -2.02% | -2.42% | |
| Form 8-K Organogenesis Holdings For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +2.72% | |
| Form 10-Q Organogenesis Holdings For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.41% | +5.08% | |
| Form 8-K Organogenesis Holdings For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | +5.08% | |
| Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.41% | +5.08% | |
| Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers | Press release | GlobeNewswire | +0.20% | -1.56% | |
| Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | +0.61% | -0.41% | |
| Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis | Press release | GlobeNewswire | +3.83% | +0.81% | |
| Form 8-K Organogenesis Holdings For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -2.09% | |
| Form 10-Q Organogenesis Holdings For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +6.37% | +16.18% | |
| Form 8-K Organogenesis Holdings For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +6.37% | +16.18% | |
| Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +6.37% | +16.18% | |
| Form ARS Organogenesis Holdings For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.85% | +9.36% | |
| Form DEF 14A Organogenesis Holdings For: Jun 15 | SEC filing · Form DEF | SEC EDGAR | +0.85% | +9.36% | |
| Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® | Press release | GlobeNewswire | +0.21% | -3.77% | |
| Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM | Press release | GlobeNewswire | +4.29% | -8.87% | |
| Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain | Press release | GlobeNewswire | +4.29% | -8.87% | |
| Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +1.76% | -1.32% | |
| Form 10-K Organogenesis Holdings For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.95% | -13.94% | |
| Form 8-K Organogenesis Holdings For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.95% | -13.94% | |
| Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue | Press release | GlobeNewswire | -2.95% | -13.94% | |
| Form 8-K Organogenesis Holdings For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +1.53% | +2.81% | |
| Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 | Press release | GlobeNewswire | -0.38% | +0.76% | |
| Avista Healthcare Partners Announces Promotions | Press release | PR Newswire | +0.65% | -3.92% | |
| Form 8-K Organogenesis Holdings For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | +0.58% | |
| Organogenesis Announces Initiation of Biologics License Application for ReNu® | Press release | GlobeNewswire | +1.04% | +1.56% | |
| Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain | Press release | GlobeNewswire | -6.68% | -1.34% | |
| Form 10-Q Organogenesis Holdings For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.09% | +10.18% | |
| Form 8-K Organogenesis Holdings For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +5.09% | +10.18% | |
| Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance | Press release | GlobeNewswire | +5.09% | +10.18% | |
| Organogenesis Applauds CMS’s Significant Step In Payment Reform | Press release | GlobeNewswire | -0.26% | -2.32% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organogenesis Holdings Inc. (ORGO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.47% | -6.10% | |
| Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.47% | -6.10% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organogenesis Holdings Inc. (ORGO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.12% | +0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Organogenesis Holdings Inc. (ORGO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.23% | -2.57% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organogenesis Holdings Inc. (ORGO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.12% | -2.90% | |
| Organogenesis Holdings Inc. (ORGO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.70% | -0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organogenesis Holdings Inc. (ORGO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -1.08% | |
| Organogenesis Holdings Inc. (ORGO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.49% | -0.12% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organogenesis Holdings Inc. (ORGO) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -1.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organogenesis Holdings Inc. (ORGO) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.24% | -0.73% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organogenesis Holdings Inc. (ORGO) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | — | — | |
| Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 | Press release | GlobeNewswire | -0.70% | -1.63% | |
| Form 8-K Organogenesis Holdings For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -12.39% | |
| Organogenesis Provides Update on Second Phase 3 ReNu® Study | Press release | GlobeNewswire | -1.18% | -12.39% | |
| Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September | Press release | GlobeNewswire | +0.51% | +4.49% | |
| Form 10-Q Organogenesis Holdings For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.83% | +9.76% | |
| Form 8-K Organogenesis Holdings For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -7.83% | +9.76% | |
| Form S-8 Organogenesis Holdings | SEC filing · Form S-8 | SEC EDGAR | -7.83% | +9.76% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORGO section they belong to.
Where else ORGO is measured.
ORGO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Organogenesis Holdings Inc. - Class A's median reaction calculated?
Every labeled ORGO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 310 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of ORGO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ORGO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.